Who global InfoBase http: www infobase who

Вид материала

Закон

Содержание Аметов А.С., И.И. Кочергина, Е.П. Елизарова. Опыт применения Дибикора при сахарном диабете 2-го типа. Проблемы эндокринологии, 2

Подобный материал:

• Electronic Data Interchange edi) Ресурсы www mcDonald's Corporation (http: //www mcdonalds, 563.02kb.
• ourism, 15.36kb.
• ru, 1763.12kb.
• rinitymission org/index php, 2637.73kb.
• a ru/stixiya/authors/griboedov, 1535.91kb.
• Информационный бюллетень московского онкологического общества. Издается с 1994 г общество, 284.71kb.
• Информационный бюллетень московского онкологического общества. Издается с 1994 г общество, 184.55kb.
• ru, 3503.92kb.
• ru, 5637.7kb.
• ru, 8160.14kb.

^

Аметов А.С., И.И. Кочергина, Е.П. Елизарова. Опыт применения Дибикора при сахарном диабете 2-го типа. Проблемы эндокринологии, 2007, 53, №4, с.44-50

Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.

Bakris G.L., Fonseca V., Katholi R.E. et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // JAMA. 2004. Vol. 292, № 18. P. 2227–2236.

Jamerson KA, Bakris GL, Wun CC et al. Rationale and design of the avoiding cardiovascular vents through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical utcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17: 793–801.

Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

Национальные клинические рекомендации «Диагностика и лечение метаболического синдрома» (второй пересмотр). Кардиоваскулярная терапия и профилактика 2009, 8(6), приложение 2.

Resnick HE, Hones K, Ruotolo G et al. Insulin resistance, the metabolic syndrome, and of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003; 26: 861-867.

Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 2013-2018.

Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men. The Framingham Heart Study. JAMA 2002; 287: 1003-1010.

Stevens J, Cai J, Pamuk E et al. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1-7.

Knowler WC, Barret-Connor E, Fowler SE et al. Diabetes Prevention Program Reserch Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.

Zimmet P, Alberti KG, Kaufman F et al.; IDF Consensus Group. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes. 2007; 8 (5): 299-306.

Knoflach M. et al. Cardiovascular risk factors and atherosclerosis in young women. Atherosclerosis risk factors in female youngsters (ARFY Study), Stroke, 2009, 40, 1063-1081).

Кисляк О.М., Перова Е.В. Состояние сосудистой стенки у подростков с метаболическим синдромом. Педиатрия 2006; 2: 23-26.

Чазова И.Е., Сметник В.П., Балан В.Е. и соавт. Консенсус российских кардиологов и гинекологов: ведение женщин в пери- и постменопаузе с сердечно-сосудистым риском. Consilium medicum 2008; 10 (6): 5-18.

White W.B., Pitt B., Preston R.A. et al. Effect of a New Hormone therapy, DRSP and 17 β-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1-8.

Caprio M, Zennaro M.-C., Mammi C. et al. Potention role of progestagens in control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. 11: 258-264.

Погосова Г.В. Признание значимости психоэмоционального стресса в качестве сердечно-сосудистого фактора риска первого порядка. Кардиология 2007; 2: 65–74.

Nemeroff C.B., O`Connor C.M. Depression as a risk factor for cardiovascular and cerebrovascular diseases: emerging data and clinical perspectives. Am Heart J 2000; 140: S5-6.

Hemingway H, Marmot M. Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. BMJ 1999; 318:1460–1467.

Lichtman J.H., Bigger J.T., James A. Blumenthal J.A., et al. Depression and Coronary Heart Disease. Circulation 2008;118:1768-1775.

Frasure-Smith N, Lespérance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 2006; 51: 730–737.

Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50:627–633.

Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 4–11.

Penninx B.W., Beekman A.T., Honig A., et al. Depression and cardiac mortality. Arch Gen Psychiatry 2001; 58: 221-227.

Kamphuis M.H., Kalmijn S., Tijhuis M.A.R. et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (Fine) study. European Journal of Cardiovascular Prevention & Rehabilitation 2006;13:199-206.

Погосова Г.В. Депрессия – новый фактор риска ишемической болезни сердца и предиктор коронарной смерти. Кардиология 2002;4:86-91.

Kubzansky LD, Kawachi I, Weiss ST, Sparrow D. Anxiety and coronary heart disease: a synthesis of epidemiological, psychological, and experimental evidence. Ann Behav Med. 1998;20(2):47-58.

Rozanski A., Blumental J.A., Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulations 1999; 99: 2192 – 217.

Roest AM, Martens EJ, de Jone P, et al. Anxiety and risk of incident coronary heart disease. A meta-analysis. J Am Coll Cardiol 2010; 56:38-46.

Чазов Е.И., Оганов Р.Г., Погосова Г.В. и соавт. Депрессивная симптоматика ухудшает прогноз у больных артериальной гипертонией и ишемической болезнью сердца: первые результаты проспективного этапа российского многоцентрового исследования КООРДИНАТА. Кардиология 2007; 10: 24–30.

Оганов Р.Г., Погосова Г.В., Шальнова С.А. и соавт. Депрессивные расстройства в общемедицинской практике по данным программы КОМПАС: взгляд кардиолога Кардиология 2005; 8: 38–44.

Погосова Г.В.Современные подходы к диагностике и лечению расстройств депрессивного спектра в общемедицинской практике. Методическое пособие для врачей. Под редакцией академика РАМН Р.Г. Оганова и профессора В.Н. Краснова. Приложение к журналу Кардиоваскулярная терапия и профилактика 2007, 1; 4-24

Zigmond A.S., Snaith R.P. Hospital Anxiety and Depression Scale. Acta Psychiat Scand 1983; 67: 361– 370.

van Melle JP, de Jonge P, Honig A, et al Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007; 190:460–466.

Glassman AH, O'Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288(6):701-709.

Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289:3106–3116.

Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004; 66:466–474.

Meigs J, H u FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291:1978–1986.

Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J M e d 2004; 350:1387–1397.

Ridker P, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–843.

Yarnell J, Patterson CC, Sweetnam PM, Lowe GDO. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J 2004; 25:1049–1056.

Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al.; PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European m en: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108:2453–2459.

RW, Anderson JL, Cannon R O III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 197:499–551. 

Wilson P. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Ability of Inflammatory Markers to Predict Disease in Asymptomatic Patients: A Background Paper. Circulation 2004; 1 10:568–571.

Hackam D, Anand SS. Emerging risk factors for atherosclerotic vascular disease. A critical review of the evidence. JAMA 2003; 290:932–940.

St-Pierre A, Cantin B, Bergeron J, Pirro M, Dagenais GR, Despres JP, et al. Inflammatory markers and long-term risk of ischemic heart disease in men. A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 2005; 182:315–321.

Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112:3080–3087.

Humphries S, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler Thromb Vasc Biol 2004; 24:628–636.

Casas J, Cooper J, Miller GJ, Hingorani AD, Humphries SE. Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Human Genetics 2006; 70 :145–169.

Yang Q, Khoury MJ, Friedman JM, Little J, Flanders W D. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005; 34:1129–1137.

Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310–315.

Myers R, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 1990; 120:963–969.

Scarabin P, Arveiler D, Amouyel P, Dos Santos C, Evans A, Luc G, et al. Plasma fibrinogen explains much of the difference in risk of coronary heart Europe an guidelines on cardiovascular disease prevention in clinical practice Fourth Joint Task Force S 107 disease between France and Northern Ireland. The PRIME Study. Atherosclerosis 2003; 166:103–109.

Hawe E, Talmud PJ, Miller GJ, H u m phries SE. Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genetics 2003; 67 (Pt 2):97–106.

Beekman M, Heijmans BT, Martin NG, Pedersen NL, Whitfield JB, DeFaire U, et al. Heritabilities of apolipoprotein and lipid levels in three countries.Twin Res 2002; 5:87–97.

Austin M, Sandholzer C, Selby JV, Newm a n B, Krauss RM, Utermann G. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genetics 1992; 51:829–840.

Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec;31(23):2844-53.

Boerwinkle E, Leffert CC, Lin J, Lackner C, C hiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52–60.

Pankow J, Folsom AR, Cush man M, Borecki IB, Hopkins PN, Eckfeldt JH, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001;1 54:681–689.

Worns M, Victor A, Galle PR, Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels: a study in twins. Genes Immun 2006; 7:600–605.

Redon R, Ishikaw a S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006;444:444–454.

Myerson S, Montgomery HE, Whittingham M, Jubb M, World MJ, Humphries SE, et al. Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. Circulation 2001; 103:226–230.

Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, et al. Plasma activity and insertion/deletion polymorphism of angiotensin Iconverting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998; 97:147–154.

Pinto Y, van Gilst WH, Kingma JH, Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and S 108 European Journal of Cardiovascular Prevention and Rehabilitation 2007, Vol 14 (suppl 2) Thrombolysis Study Investigators. J Am Coll Cardiol 1995; 25:1622–1626.

Andersson B, Sylven C. The D D genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28:162–167.

Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41:47–53.

Arias-Vasquez A, Sayed-Tabatabaei FA, Schut AF, Hofman A, Bertolli-Avella AM, Vergeer JM, et al. Angiotensin converting enzyme gene, smoking and mortality in a population-based study. Eur J Clin Invest 2005; 35:444–449.

Goldstein J, Brown M. Familial hypercholesterolaemia. In: Scriver C BA, Sly W, Valle D, editors. The metabolic basis of inherited disease. N e w York:Mc Graw Hill; 1995:1215–1245.

Fouchier S, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genetics 2001; 109:602–615.

Heath K, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J H u m Genetics 2001; 9:244–252.

Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet 1972; 1:393–399.

Goldstein J, Hazzard W R , Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973; 52:1533–1543.

von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 2006; 186:231–239.

Wilson P, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1997; 97:1837–1847.

Chasman D, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. J Am Med Assoc 2004; 291:2821–2827.

Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genetics M e d 2005; 7:97–104

Bots ML, Dujk JM, Oren A, Grogge D. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence // J Hypertens.- 2002.-V. 20.-P.2317-2326.

Zanchetti A., Bond M.G., Henning M. et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European lacidipine study on atherosclerosis (ELSA) // J. Hypertens. – 1998. – Vol.16, №7. – P.949-961.

O’Leary D.R., Polak J.F., Kronmal R.A. et al. Carotid artery intima and media thickness and a risk for myocardial infarction and stroke in elder patients // N. Eng. J. Med. – 1999. – Vol.340. – P.14-22.

Cournot M et al. AHJ 2009;158(5):845-851

Salonen J.T., Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary artery disease // Arterioscler. Thromb. Vascul. Biol. – 1991. – Vol.11. – P.1241-1249.

Hodis H.M., Mack W.L., Labree L. at al. The role of carotid arterial intima-media thickness in predicting coronary events // Ann. Intern. Med. – 1998. – Vol. 128. – P.262-269.

Sutton T.K., Alcorn H.G., Herzog H. et al. Morbidity, mortality and antihypertensive treatment effects by extent of atherosclesosis in older adults with isolated systolic hypertension // Stroke. – 1995. – Vol.26. – P.1319-1324.

Willum-Hansen T, Staessen JA, Torp-Pedersen C et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population // Circulation. - 2006.-Vol. 113.-P.664-670.

Amar J., Ruidavets J.B., Charmontin B. et al. Arterial stiffness and cardiovascular risk factors in a population-based study // J. Hypertens. – 2001. – Vol.19, №3. – P. 381-387.

Blacher J, Guerin A, Marchias SJ et al. Impact of aortic stiffness on survival in end-stage renal disease//Circulation.- 1999.-Vol.99.-P.2434-2439.

Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness as an independent predictor of primary coronary events in hypertensive patients: a longitudinal study// Hypertension.- 2002.-V.39.-P.10-15.

Van Bortel LM, Duprez D, Safar ME et al. Applications of the arterial stiffness, Tsk Forse II: recomendations for user procedures// Am. J. Hypertes.- 2002.-Vol. 15.-P.445-452.

Laurent S., Cockcroft J., Van Bortel L. et al. for the European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications // Eur. Heart J.- 2006. – Vol. 27, № 21. - P. 2588 –2605.

McPhail IR, Spittell PC, Weston SA, et al. Intermittent claudication: an objective office-based assessment. J Am Coll Cardiol. 2001;37:1381–1385.

Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med. 1993;118:712–719.

Perticone F., Cerevalo R., Rujia A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients // Circulation. – 2001.-Vol.104.-P.191-196.

Celermajer DS. Soresen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.

Иванова О.В., Рогоза А.Н., Балахонова Т.В., Соболева Г.Н., Атьков О.Ю., Карпов Ю.А. Определение чувствительности плечевой артерии к напряжению сдвига на эндотелии как метод оценки состояния эндотелийзависимой вазодилатации с помощью ультарзвука выского разешения у больных с артериальной гипертонией // Кардиология. – 1998.- Vol. 8. C. 37-40.

Anderson TJ, Assessment and treatment of endothelial dysfunction in humans // J. Am. Coll. Cardiol. – 1999. –Vol. 34.-P.631-638.

Hamburg N, Keyes, M.G. Larson et al. Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study.//Circulation 2008;VOL.117.-P.2467-2474.

Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801–9.

Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355–74.

Tanenbaum SR, Kondos GT, Veselik KE, et al. Detection of calcific deposits in coronary arteries by ultrafast computed tomography and correlation with angiography. Am J Cardiol 1989;63:870 –2.

Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol 2001;21:1618 –22.

Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71.

Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32.

Budoff MJ, Diamond GA, Raggi P, et al. Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 2002;105:1791– 6.

Haberl R, Becker A, Leber A, et al. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 2001;37:451–7.

Knez A, Becker A, Leber A, et al. Relation of coronary calcium scores by electron beam tomography to obstructive disease in 2,115 symptomatic patients. Am J Cardiol 2004;93:1150 –2.

Johnson KM, Dowe DA. The detection of any coronary calcium outperforms Framingham risk score as a first step in screening for coronary atherosclerosis. AJR Am J Roentgenol. 2010 May;194(5):1235-43.

Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS; American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007 Jan 23;49(3):378-402.

Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80(10):1270-7.

Willcox BJ, He Q, Chen R, Yano K, Masaki KH, Grove JS, Donlon TA, Willcox DC, Curb JD. Midlife risk factors and healthy survival in men. JAMA 2006;296:2343-2350.

Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1:8–18.

Fox C, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291:844–850.

Mann J, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629–636.

Anevekar N, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Eng J Med 2004; 351:1285–1295.

Cooper W, O’Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, et al. Impact of renal dysfunction on outcomes of coronary bypass surgery: results from the Society of Thoracic Surgeons’s National Adult Cardiac database. Circulation 2006; 1 13:1063–1070.

Hemmelgarn B, Southern DA, Humphries KH, Culleton BF, Knudson ML, Ghali WA. Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization. Eur Heart J 2006; 27:1191–1197.

Hillege H, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671–678.

Leithe M, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 1984; 69:57–64.

Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 161:2001:886–891.

Моисеев В.С., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002;11(3):16-18.

Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004;6:39-46.

Drüeke et al. Effects of Normalizing Hemoglobin in Chronic Kidney Disease Patients. NEJM 2006, 355: 2071-84.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-32.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-98.

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB; RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11(8):795-801.

Stramba-Badiale M., Fox K.M. , Priori S.G., Collins P., Daly C., Graham I., Jonsson B., Schenck-Gustafsson K., Tendera M. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27 (8): 994-1005.

Mosca L., Appel L.J., Benjamin E.J., Berra K., Chandra-Strobos N., Fabunmi R.P., Grady D., Haan C.K., Hayes S.N., Judelson D.R., Keenan N.L., McBride P., Oparil S., Ouyang P., Oz M.C., Mendelsohn M.E., Pasternak R.C., Pinn V.W., Robertson R.M., Schenck-Gustafsson K., Sila C.A., Smith S.C. Jr, Sopko G., Taylor A.L., Walsh B.W., Wenger N.K., Williams C.L.; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004 Feb 10;109(5):672-93.

Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J., Ganiats T.G., Gomes A.S., Gornik H.L., Gracia C., Gulati M., Haan C.K., Judelson D.R., Keenan N., Kelepouris E., Michos E.D., Newby L.K., Oparil S., Ouyang P., Oz M.C., Petitti D., Pinn V.W., Redberg R.F., Scott R., Sherif K., Smith S.C., Jr, Sopko G., Steinhorn R.H., Stone N.J., Taubert K.A., Todd B.A., Urbina E., Wenger N.K., Expert Panel/Writing Group, Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. J Am Coll Cardiol 2007 49: 1230-1250

Thom T, Haase N, Rosamond W, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published corrections appear in Circulation 2006;113:e696 and Circulation 2006;114:e630] Circulation 2006;113:e85-e151.

Manolio T.A., Pearson T.A., Wenger N.K., Barrett-Connor E., Payne G.H., Harlan W.R. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992 Jan-Mar;2(1-2):161-76.

Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study BMJ 2003;326:845-852.

Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular Health After Maternal Placental Syndromes (CHAMPS): population-based retrospective cohort study Lancet 2005;366:1797-1803.

Jacobs A.K., Kelsey S.F., Brooks M.M., Faxon D.P., Chaitman B.R., Bittner V., Mock M.B., Weiner B.H., Dean L., Winston C., Drew L., Sopko G. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). Circulation. 1998 Sep 29;98(13):1279-85.

Stramba-Badiale M., Priori S.G. Gender-specific prescription for cardiovascular diseases? Eur Heart J 2005; 26(16): 1571-1572.

Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., Hennekens C.H., Buring J.E. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005; 352:1293-1304.

Kim C., Hofer T.P., Kerr E.A. Review of Evidence and Explanations for Suboptimal Screening and Treatment of Dyslipidemia in Women. A Conceptual Model. J Gen Intern Med. 2003 October; 18(10): 854–863.

Bird CE, Fremont A, Wickstrom S, Bierman AS, McGlynn E. Improving women’s quality of care for cardiovascular disease and diabetes: the feasibility and desirability of stratified reporting of objective performance measures. Women's Health Issues. 2003; 13 (4):150-157.

Boreham C., Riddock C. The physical activity, fitness and health of children. J Sports Sci. 2001; 7: 215-229.

Daniels S. Cardiovascular risk factors and atherosclerosis in children and adolescence. Curr Atheroscl Rep. 2001; 3: 479-485.

Misra A. Risk factors for atherosclerosis in young individuals. J Cardiovasc Risk 2000; 7: 215-229.

Kavey R-E.W., Allada V., Daniels S.R., Hayman L.L., McCrindle B.W., Newburger J.W., Parekh R.S., Steinberger J. Cardiovascular Risk Reduction in High-Risk Pediatric Patients. A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Endorsed by the American Academy of Pediatrics. Circulation 2006;114;2710-2738.

Varvarigou AA. Intrauterine growth restriction as a potential risk factor for disease onset in adulthood. J Pediatr Endocrinol Metab. 2010 Mar;23(3):215-24.

Российские Национальные рекомендации ВНОК по диагностике, лечению и профилактике артериальной гипертензии у детей и подростков. Кардиоваскулярная терапия и профилактика, 2009; 8 (4). Приложение 1.

Kavey R-EW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 2003;107;1562-1566.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.

Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166–181.

Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):234S–264S.

Patrono C. Aspirin resistance: definition, mechanisms and clinical readouts. J Thromb Haemost 2003;1:1710–1713.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860.

Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405–410.

US Preventive Services Task Force: Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services TaskForce recommendation statement. Ann Intern Med 2009;150:396–404.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134–2141.

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.

American Diabetes Association. Standards of Medical Care in Diabetes—2011 Diabetes Care January 2011 34:S11-S61.

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010 Dec 7;56(24):2051-66.

Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 2005;366:1607-1621.

Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 2005;352:1179-1189.

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 2001;345:494-502.

Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 2001;358:527-533.

Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 Jul;28(13):1598-660. Epub 2007 Jun 14.

European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D; ESC Committee for Practice Guidelines, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P; EACTS Clinical Guidelines Committee, Kolh P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, Kearney P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel de la Riviere A, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTSА). Eur Heart J. 2010 Oct;31(20):2501-55.

Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009 Dec 1;54(23):2205-41.

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312.

European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. Epub 2008 May 6.

Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T; American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006 Feb;37(2):577-617.

Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research.Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Jan;42(1):227-76.

Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006 Aug;27(16):1979-2030.

ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066-78. Epub 2009 Mar 31. 346

Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 Jan;28(2):230-68. Epub 2007 Jan 26.

The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.

Barron HV, Viskin S, Lundstrom RJ, Wong CC, Swain BE, Truman AF, Selby JV. Effect of beta-adrenergic blocking agents on mortality rate in patients not revascularized after myocardial infarction: data from a large HMO. Am Heart J 1997;134:608-13.

Chae CU, Hennekens CH . Beta blockers. In: Hennekens CH, ed. Clinical trials in cardiovascular disease: a companion to Braunwald’s Heart Disease. Philadelphia, PA: WB Saunders Co Ltd; 1999:79-94.

Antman E, Braunwald E. Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1251.

Boersma E, Poldermans D, Bax JJ, Steyerberg EW, Thomson IR, Banga JD, van De Ven LL, van Urk H, Roelandt JR. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001;285:1865–1873.

Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349–361.

Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341: 1789–1794.

Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–1847.

Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR. Perioperative betablockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J Vasc Surg 2005;41:602–609.

Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Norgaard P, Fruergaard K, Bestle M, Vedelsdal R, Miran A, Jacobsen J, Roed J, Mortensen MB, Jorgensen L, Jorgensen J, Rovsing ML, Petersen PL, Pott F, Haas M, Albret R, Nielsen LL, Johansson G, Stjernholm P, Molgaard Y, Foss NB, Elkjaer J, Dehlie B, Boysen K, Zaric D, Munksgaard A, Madsen JB, Oberg B, Khanykin B, Blemmer T, Yndgaard S, Perko G, Wang LP, Winkel P, Hilden J, Jensen P, Salas N. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006;332:1482.

Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713–1720.

Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006;152:983–990.

Zaugg M, Bestmann L, Wacker J, Lucchinetti E, Boltres A, Schulz C, Hersberger M, Kalin G, Furrer L, Hofer C, Blumenthal S, Muller A, Zollinger A, Spahn DR, Borgeat A. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. Anesthesiology 2007;107:33–44.

Bangalore S,Wetterslev J, Pranesh S, Sahney S, Gluud C, Messerli FH. Perioperative b blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008;372:1962–1976.

Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F, Hoeks SE, Vanhorebeek I; Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology; European Society of Anaesthesiology. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).Eur Heart J. 2009 Nov;30(22):2769-812. Epub 2009 Aug 27.

Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994 May 7;343(8906):1115-22.

ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995 Mar 18;345(8951):669-85.

Claudio Napoli.  Safety and Efficacy of the bi-Sulfydryl ACE-Inhibitor Zofenopril in the Management of Cardiovascular Disease. Clinical Medicine: Therapeutics 2009:1; 847-853.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145-53.

Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).Lancet. 2003 Sep 6;362(9386):782-8.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 Jun;28(12):1462-536. Epub 2007 Jun 11.

IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002 Apr 13;359(9314):1269-75.

Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003;14:171–179.

Cross HR. Trimetazidine for stable angina pectoris. Expert Opin Pharmacother 2001;2:857–875.

Н.П.Кутишенко, Н.А.Дмитриева, Ю.В.Лукина, М.П.Козырева, Ю.Э.Семенова, А.Д.Деев, С.Ю.Марцевич. Влияние Милдроната на эффективность антиангинальной терапии больных стабильной стенокардией напряжения. Рациональная Фармакотерапия в кардиологии, 2005, №2.

И.В. Сергиенко, В.В. Кухарчук, С.А. Габрусенко, В.В. Малахов, В.П. Масенко, М.И. Трипотень, Т.В. Балахонова. Оценка влияния комбинированной терапии милдронатом на липидный спектр, факторы воспаления и функцию эндотелия у больных ишемической болезнью сердца. РФК 2007;3:10-14

И.В. Дамулин, Н.Н. Коберская, Л.М. Антоненко. Влияние Милдроната на когнитивные нарушения при дисциркуляторной энцефалопатии: клинико-электрофизиологическое исследование; Неврологический журнал, 1. 2006, том 11

Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 2004 Jan;25(1):25-31.

Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Tex Heart Inst J (2004) 31:28–32.

AHA; ACC; National Heart, Lung, and Blood Institute, Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006 May 16;47(10):2130-9.